Navigation Links
Reportlinker Adds U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
Date:5/9/2011

NEW YORK, May 9, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments

http://www.reportlinker.com/p0490687/US-Rheumatoid-Arthritis-Market-Assessment-of-Biologics-and-New-Treatments.html

This research service covers the U.S. rheumatoid arthritis (RA) market from 2007 to 2017, with 2010 as the base year. Included in this research service are products currently in the market, products in development, and patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented to overcome listed industry challenges. This research service does not include market revenue forecasts for DMARDs. This research service highlights product forecasts for biologic products as well as small molecules near launch.

Table of Contents

Scope

10

Methodology

Methodology

11

Market Introduction

RA Background

13

Epidemiology

14

Risk Factors

15

Diagnosis

16

Treatment Paradigm

17

Patient Outlook

Patient Forecast of RA in the United States

19

RA Patients Requiring Add-on Therapy, Forecast in the United States

20

Patients Taking Add-on Therapy Forecast in the United States

21

Industry Challenges

23

Current Treatments

28

Key Trends

31

Market Drivers and Restraints

33

Market Drivers

34

Market Analysis and Forecasts

Market Engineering Measurements

41

Revenue Forecastsfor Biologics and New Treatments

42

Product Forecasts

Forecasting Assumptions

44

Enbrel: Revenue Forecasts

45

Humira: Revenue Forecasts

46

Remicade: Revenue Forecasts

47

Cimzia: Revenue Forecasts

48

Simponi: Revenue Forecasts

49

Rituxan: Revenue Forecasts

50

Orencia: Revenue Forecasts

51

Actemra: Revenue Forecasts

52

CP-690,550: Revenue Forecasts

53

FostamatinibDisodium: Revenue Forecasts

54

Competitive Analysis

Rheumatoid Arthritis Market: Competitive Structure

56

Rheumatoid Arthritis Market: Revenue Market Share Analysis

57

Pipeline Analysis

RA Competitive Landscape

59

Late-stage RA Compounds: Clinical Trial Overview

60

U.S. Small Molecule Approval Timeline

62

Strategic Recommendations

Strategic Recommendations

64

Conclusions

67

About Frost & Sullivan

Who is Frost & Sullivan

69

What Makes Us Unique

70

T.E.A.M. Methodology

71

Global Perspective

72

List of Figures

Rheumatoid Arthritis Market: Patient Forecast (U.S.), 2007-2017

19

Rheumatoid Arthritis Market: Patient Requiring Add-on Therapy Forecast (U.S.), 2007-2017

20

Rheumatoid Arthritis Market: Total RA Anti-TNF Population Forecast (U.S.), 2007-2017

21

Rheumatoid Arthritis Market: Impact of Industry Challenges (U.S.), 2011-2017

23

Rheumatoid Arthritis Market: Current Treatments (U.S.), 2010

28

Rheumatoid Arthritis Market: Current Biologic Therapies (U.S.), 2010

29

Rheumatoid Arthritis Market: Market Drivers Ranked in the Order of Impact (U.S.), 2011-2017

34

Rheumatoid Arthritis Market: Market Restraints Ranked in the Order of Impact (U.S.), 2011-2017

37

Rheumatoid Arthritis Market : Revenue Forecasts for Biologics and New Treatments (U.S.), 2010

42

Rheumatoid Arthritis Market: Forecasting Assumptions (U.S.), 2010

44

Rheumatoid Arthritis Market: Revenue Forecasts for Enbrel(U.S.), 2007-2017

45

Rheumatoid Arthritis Market: Revenue Forecasts for Humira(U.S.), 2007-2017

46

Rheumatoid Arthritis Market: Revenue Forecasts for Remicade(U.S.), 2007-2017

47

Rheumatoid Arthritis Market: Revenue Forecasts for Cimzia(U.S.), 2007-2017

48

Rheumatoid Arthritis Market: Revenue Forecasts for Simponi(U.S.), 2007-2017

49

Rheumatoid Arthritis Market: Revenue Forecasts for Rituxan(U.S.), 2007-2017

50

Rheumatoid Arthritis Market: Revenue Forecasts for Orencia(U.S.), 2007-2017

51

Rheumatoid Arthritis Market: Revenue Forecasts for Actemra(U.S.), 2007-2017

52

Rheumatoid Arthritis Market: Revenue Forecasts for CP-690,550 (U.S.), 2007-2017

53

Rheumatoid Arthritis Market: Revenue Forecasts for FostamatinibDisodium (U.S.), 2007-2017

54

Rheumatoid Arthritis Market: Competitive Structure for Biologics and New Treatments (U.S.), 2010

56

Rheumatoid Arthritis Market : Market Share Analysis for Biologics(U.S.), 2010

57

Rheumatoid Arthritis Market: Clinical Trial Overview (U.S.), 2010

60

List of Charts

Rheumatoid Arthritis Market: Treatment Paradigm (U.S.), 2010

17

Rheumatoid Arthritis Market: Market Drivers and Restraints (U.S.), 2011-2017

33

Rheumatoid Arthritis Market: Market Engineering MeasurementsforBiologics and New Treatments (U.S.), 2010

41

Rheumatoid Arthritis Market: Revenue Forecasts for Biologics and New Treatments (U.S.), 2007-2017

42

Rheumatoid Arthritis Market: Revenue Forecasts for Enbrel(U.S.), 2007-2017

45

Rheumatoid Arthritis Market: Revenue Forecasts for Humira(U.S.), 2007-2017

46

Rheumatoid Arthritis Market: Revenue Forecasts for Remicade(U.S.), 2007-2017

47

Rheumatoid Arthritis Market: Revenue Forecasts for Cimzia(U.S.), 2007-2017

48

Rheumatoid Arthritis Market: Revenue Forecasts for Simponi(U.S.), 2007-2017

49

Rheumatoid Arthritis Market: Revenue Forecasts for Rituxan(U.S.), 2007-2017

50

Rheumatoid Arthritis Market: Revenue Forecasts for Orencia(U.S.), 2007-2017

51

Rheumatoid Arthritis Market: Revenue Forecasts for Actemra(U.S.), 2007-2017

52

Rheumatoid Arthritis Market: Revenue Forecasts for CP-690,550 (U.S.), 2007-2017

53

Rheumatoid Arthritis Market: Revenue Forecasts for FostamatinibDisodium (U.S.), 2007-2017

54

Rheumatoid Arthritis Market: Market Share Analysis for Biologics (U.S.), 2010

57

Rheumatoid Arthritis Market: Competitive Landscape (U.S.), 2010

59

Rheumatoid Arthritis Market: Small Molecule Approval Timeline (U.S.), 2011-2017

62

Rheumatoid Arthritis Market: Key Stakeholders (U.S.), 2010

64

To order this report:

: U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
4. Reportlinker Adds Global Medical Devices Industry Outlook to 2010: Marketing And Sales Strategies And The Impact of Recession And Recovery
5. Reportlinker Adds Reinventing Pharmaceutical Sales Forces
6. Reportlinker Adds Computer Assisted Coding Of Medical Information Market Shares, Strategies, and Forecasts 2008 to 2014
7. Reportlinker Adds Global Drug Manufacturing Industry Outlook to 2010: Marketing and Sales Strategies and the Impact of Recession and Recovery
8. Reportlinker Adds Global Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015
9. Reportlinker Adds The Middle Eastern Pharmaceutical Market Outlook To 2014: Policy environment, market structure, competitive landscape, growth opportunities
10. Reportlinker Adds Global Top 10 Chemical Companies -- Industry, Financial and SWOT Analysis
11. Reportlinker Adds Pharma 101: An Overview of the Life Sciences Industry (Analyst Insight)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):